- AlgenScribe has completed a strategic refinancing, with an initial tranche received in December 2024, bringing the total funds raised since its inception to approximately €1 million.
- Team Nice Côte d’Azur supported the company’s establishment within the Nice metropolitan area, facilitating its integration into the local ecosystem.
- A fruitful collaboration with the Imagine Institute led to a three-year grant from the French National Research Agency (ANR) in August 2024.
On January 7, 2025, AlgenScribe, a key player in genomic medicine, announced the completion of a strategic refinancing with its long-standing partners. This financial support, including an initial tranche received in December 2024, raises the company’s total funding to approximately €1 million since its creation in 2022.
This refinancing represents a significant milestone in the development of AlgenScribe’s innovative genome-editing platform, designed to address critical challenges in gene therapy. The company’s focus includes improving the efficiency of gene replacement, a key issue in oncology and genetic disorders.
A Unique Toolbox for Promising Applications
algenScribe leverages a molecular biology platform composed of licensed technological modules and international collaborations. Developed in its laboratories in Nice and Saclay, this platform aims to enhance the insertion of corrective genes by exploiting synergistic combinations of molecular tools.
According to Frédéric Zampatti, co-founder and president of the company: “The goal of AlgenScribe is to use the best combination of synergistic tools to ex vivo correct the genome of cells, which, once re-implanted or reinfused, could treat the targeted disease.”
In August 2024, AlgenScribe’s collaboration with the Imagine Institute secured a three-year grant from the French National Research Agency. This support advances the development of proof-of-concept studies for rare diseases, opening new therapeutic perspectives.
A Successful Pre-Seed Round in 2023
In June 2023, AlgenScribe reached another significant milestone with its first pre-seed funding round. Secured through business angels organized under YES Invest, this funding enabled the company to intensify research activities and conduct proof-of-concept studies on two rare diseases and one blood disorder.
This funding round demonstrated the sector’s interest in AlgenScribe’s technologies, particularly in increasing the number of edited cells while reducing undesirable mutations.
Strategic Establishment in Nice Côte d’Azur
Supported by Team Nice Côte d’Azur during its establishment, AlgenScribe’s presence in the Nice metropolitan area is a major asset for its development. Backed by the Provence Côte d’Azur incubator and the Région Sud, the company benefits from a rich ecosystem in biotechnology and research infrastructure.
Funding and Development Outlook
Building on these achievements, AlgenScribe is now seeking to raise an additional €1 to €3 million by the end of 2025. These funds will be dedicated to validating initial proof-of-concept studies and exploring broader therapeutic applications.
The company is supported and funded by Provence Côte d’Azur Incubator (PCA), Région Sud, BPI France, and YES Invest (Yvelines Essonne Saclay Invest).
AlgenScribe was advised by Maître Sidonie Hill from the STH2 law firm.
Sources : algenScribe press release, Team Nice Côte d’Azur – Photo : All rights reserved.
